Sudeep Pharma Ltd
- Market Cap ₹ 0.00 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 0.00
- Book Value ₹
- Dividend Yield %
- ROCE 35.6 %
- ROE 32.8 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 50.4% CAGR over last 5 years
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 123 | 215 | 343 | 459 | 502 | |
| 98 | 171 | 276 | 277 | 311 | |
| Operating Profit | 25 | 44 | 67 | 182 | 191 |
| OPM % | 21% | 20% | 20% | 40% | 38% |
| 3 | 3 | 7 | 6 | 9 | |
| Interest | 1 | 1 | 2 | 5 | 7 |
| Depreciation | 3 | 4 | 5 | 9 | 11 |
| Profit before tax | 25 | 43 | 69 | 175 | 183 |
| Tax % | 27% | 22% | 27% | 24% | 24% |
| 18 | 33 | 50 | 133 | 139 | |
| EPS in Rs | |||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 14% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 50% |
| 3 Years: | 40% |
| TTM: | 4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 33% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 10 |
| Reserves | 80 | 113 | 162 | 355 | 481 |
| 20 | 31 | 84 | 78 | 140 | |
| 30 | 67 | 97 | 80 | 86 | |
| Total Liabilities | 131 | 213 | 344 | 514 | 717 |
| 60 | 68 | 137 | 180 | 189 | |
| CWIP | 8 | 24 | 8 | 45 | 88 |
| Investments | 6 | 19 | 0 | 0 | 0 |
| 57 | 102 | 199 | 289 | 439 | |
| Total Assets | 131 | 213 | 344 | 514 | 717 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 10 | 35 | -3 | 66 | 49 | |
| -22 | -40 | -38 | -49 | -79 | |
| 12 | 13 | 51 | -13 | 53 | |
| Net Cash Flow | -0 | 8 | 10 | 4 | 23 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 90 | 94 | 114 | 115 | 135 |
| Inventory Days | 77 | 79 | 104 | 150 | 309 |
| Days Payable | 70 | 79 | 76 | 115 | 145 |
| Cash Conversion Cycle | 97 | 93 | 142 | 151 | 298 |
| Working Capital Days | 46 | 13 | 30 | 99 | 144 |
| ROCE % | 36% | 36% | 36% |
Documents
Annual reports
No data available.